This World Lung Cancer Day, join us to raise support for those affected by one of the most common cancers in the world. In this video interview, Head of the Cancer Institute in Shaare Zedek…

Expert Opinion | Dr. Nir Peled | Liquid biopsy as a first line diagnostic tool for NSCLC patients   

Some of the biggest names in medical oncology from Asia, Middle East and Africa gathered at Guardant Health AMEA’s new office on 27 March to share their views in an engaging panel discussion on transforming…

Guardant by the Bay with Singapore Cancer Society beneficiaries   

September marks Prostate Cancer Awareness Month. Check out this study (https://jitc.bmj.com/content/8/2/e001065) which concluded that the use of a well-validated cfDNA NGS liquid biopsy such as the Guardant360®️ test to identify metastatic prostate cancer patients with…

Patient education video featuring Dr. Akhil Chopra from OncoCare Cancer Centre   

Hear from Prof. Cho Byoung Chul, Chief of the Lung Cancer Center in Yonsei Cancer Center in Seoul, South Korea as he shares his experience of using the Guardant360® test in his clinic. Prof. Cho…

The quick turnaround time of the Guardant360® liquid biopsy test allows for shorter time to treatment for patients with advanced stage cancer compared to tissue biopsies. Guardant360 test results are delivered to physicians in seven…

Speak to your oncologist about ordering a comprehensive liquid biopsy like the Guardant360® test to help guide treatment decisions for you, so that you can get suitable treatment sooner. Visit us online at www.guardanthealthamea.com to find out…

Expert Opinion | Dr. Nitesh Rohatgi | The importance of ctDNA-based response monitoring   

There is no ‘one size fits all’ approach when it comes to treating cancer. As your cancer diagnosis could differ from others’, the treatment or therapy you may require could be different as well. What…

Watch this live interview on CNBC Squawk Box Asia where our CEO, Simranjit Singh talks about Guardant Health AMEA’s growth strategy for the next two years and the advantages of using liquid biopsies such as…

In celebration of International Women's Day, Guardant Health AMEA would like to recognize the dedication and hard work of all the wonderful women in our organization. Together, we can help to conquer cancer. Enjoy this 2-minute video:…

Inviting all Oncologists! Register @ https://lnkd.in/gePw-3M for this 20-minute webinar session today at 7.30pm (IST) on the Value of Comprehensive Genomic Profiling in Modern Lung Cancer Practice led by Dr. Natasha B. Leighl, a distinguished medical…

Guardant Health Inc. is proud to announce that the Guardant360 CDx test has received the CE-mark for comprehensive tumor mutation profiling across all solid cancers. This is an important step to make the test more widely…

According to the International Agency for Research on Cancer, colorectal cancer is the third most common cancer in men and the second most common cancer in women worldwide. In observance of colorectal cancer awareness this…

The American Society of Clinical Oncology (ASCO) has recently named Molecular Profiling Driving Progress in Gastrointestinal Cancers as the Advance of the Year in Clinical Cancer Advances 2021. https://lnkd.in/gAjNrA4 Research has shown that targeting human epidermal…

This webinar will feature three speakers from Guardant Health, Inc., namely Justin Odegaard, Christopher Vandepas and Brenton F.. The session will be moderated by Michelle Lee from Guardant Health AMEA. We look forward to your participation. Contact us at press@guardantamea.com to register before 9…

Guardant Health, Inc. has recently launched Guardant Reveal™, the first blood-only liquid biopsy test for residual disease and recurrence monitoring of early-stage colorectal cancer patients. https://lnkd.in/g2MiCaj Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the…

Calling all medical oncologists! Join us on 22 February for a Webinar Panel Discussion on Recent Advances in Lung Cancer. This webinar will feature four speakers, namely Dr. Herbert Loong from Hong Kong, Marwan Akasheh from Jordan, Dr.…

Happy Chinese New Year from all of us at www.guardanthealthamea.com

Congratulations to #DaiichiSankyo and #AstraZeneca for its recent approval of ENHERTU® (fam-trastuzumab deruxtecan-nxki) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma…

Congratulations to #Yuhan for its recent approval of Leclaza (Lazertinib) for lung cancer treatment by Korea’s Ministry of Food and Drug Safety. https://lnkd.in/grU_-jC Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy.…

In commemoration of World Cancer Day, we are delighted to announce that we have submitted our application for regulatory approval of Guardant360 CDx in Japan. See full press release here: https://lnkd.in/e3eQEmE We commemorate World Cancer Day…

Visit our virtual booth at the 2020 IASLC World Conference on Lung Cancer taking place as a Worldwide Virtual Event from January 28-31, 2021. https://lnkd.in/exYNn59 Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the…

Check out these Guardant360® abstracts at the 2020 IASLC World Conference on Lung Cancer taking place as a Worldwide Virtual Event from January 28-31, 2021. https://lnkd.in/exYNn59 Visit us online @ guardanthealthamea.com to find out more about Guardant360®,…

Save the date and visit our virtual booth at the 2020 IASLC World Conference on Lung Cancer taking place as a Worldwide Virtual Event from January 28-31, 2021. This is the world's largest international gathering…

Recently, Guardant Health, Inc. announced exciting updates for 2021 which is bringing the company closer to its vision of transforming cancer care across the continuum. This includes the introduction of Guardant Reveal, the first blood-only liquid…

Check out this interview featured in Singapore Business Review Awards where our CEO, Simranjit Singh, shares how putting patients first, challenging the norms and collaboration are some of the key reasons behind Guardant Health AMEA's success in winning…

To all oncologists who have been ordering the Guardant360® test, A Big Thank You for your unwavering support in 2020. We look forward to working closely with you this year and help advanced cancer patients…

Merry Christmas and Happy New Year! - from all of us at guardanthealthamea.com

Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa.  Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in…

Our CEO, Simranjit Singh, has been listed as one of the Top 25 Voices in Precision Medicine in Asia. Check out this whitepaper @ https://lnkd.in/gmi7zqp, presented to you by BIS Research and #insightMonk. Visit us online @ guardanthealthamea.com to find out…

We are hiring! Join us as an Assistant Product Manager. Send in your application by 25 Dec 2020. Apply here: https://lnkd.in/g6fE7ND Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid…

Congratulations to the Guardant Health AMEA team on winning Team of the Year and Executive of the Year in the Healthcare category at the SBR Management Excellence Awards 2020! It is a great honour for…

Calling All Pharmaceutical Industry Professionals and Medical Oncologists! Join us on 11 Dec at 1pm (GMT+9hrs) for a Webinar Discussion on "Liquid versus Tissue Biopsy for Clinical Trial Enrollment in Gastrointestinal Cancers". This webinar will…

 Watch this four-minute video on Lung Cancer Patient Cases, where the Guardant360® test was used, resulting in the patients responding well to treatment. The findings from these two patient cases were presented by Prof.…

Watch this four-minute video on Lung Cancer Patient Cases, where the Guardant360® test was used, resulting in the patients responding well to treatment. The findings from these two patient cases were presented by Prof. Byoung…

Inviting all oncologists! Join us on 30 November for a Webinar Discussion on the Applications of Liquid Biopsy in advanced NSCLC: Perspectives from the pulmonology clinic. This webinar will be led by Dr. Amir Onn,…

The Guardant360 test can provide comprehensive genomic profiling information which helps to guide treatment decisions for advanced lung cancer patients. In this patient case, the Guardant360 test detected an uncommon exon 19 deletion that was…

Calling all medical oncologists! If you have registered for ESMO Asia Virtual Congress 2020 taking place from 20th to 22th November, book a meeting slot with us today at the following link: https://lnkd.in/gcYaF-z  and find out…

Calling all medical oncologists! Meet us at our ESMO Asia Virtual Booth https://lnkd.in/gG8fi6h today and tomorrow at any time between 12pm and 7pm (GMT+8 hours) and find out more about the Guardant360 test and how it…

Visit us today at our virtual booth (https://lnkd.in/gG8fi6h) to find out more about the Guardant360 test and how it can help to guide treatment decisions that are being made by oncologists in Asia, Middle East…

Inviting all medical oncologists! Join us on 25 November for a Webinar Discussion on the Recent Advances in Liquid Biopsy. This webinar, jointly organized by Guardant Health AMEA and St. Luke's Medical Centre, will be…

ESMO Asia Virtual Congress 2020 is now "live". Visit us at our virtual booth from 20 Nov to 22 Nov to find out more about the Guardant360 test and how it can help advanced cancer…

1 Day to go to ESMO Asia Virtual Congress 2020 taking place from 20-22 Nov 2020. Save the date. We look forward to seeing you at our virtual booth. https://lnkd.in/gd_QXr4 

Check out our poster presentations which are now "live" at ESMO Asia Virtual Congress 2020 and learn more about Guardant360®, the global leader in liquid biopsy. The poster IDs are highlighted for your easy reference.…

Visit us today at our virtual booth at ESMO Asia Virtual Congress 2020, taking place from 20th to 22th November. Download this PDF to click on the links. We look forward to sharing with you about the…

With a simple blood draw, the Guardant360 test is helping to guide treatment decisions for advanced lung cancer patients. In this patient case, the Guardant360 test detected BRAF V600E, a targetable alteration that was not…

Happy Diwali! - from all of us at guardanthealthamea.com  

8 Days to go to ESMO Asia Virtual Congress 2020 taking place from 20-22 Nov 2020. Save the date. We look forward to seeing you at our virtual booth. https://lnkd.in/gd_QXr4 Visit us online @ guardanthealthamea.com to find out…

Calling all medical oncologists! Join us on 18 November for a Webinar Discussion on the evolving role of comprehensive liquid biopsies in advanced stage solid tumors. This webinar will be led by Dr. Steve Olsen, our…

Our CEO, Simranjit Singh was recently featured in BioSpectrum Asia’s online magazine where he shared insights into the liquid biopsy market and how our Guardant360 test can help guide treatment decisions for advanced stage cancer patients with solid…

For oncologists, complete biomarker testing is becoming increasingly important before starting treatment for advanced lung cancer patients. Do not proceed with first-line therapy without a clear view ahead. Liquid biopsies such as the Guardant360 test…

If you are an oncologist, you’re in the driver’s seat when making treatment decisions for your advanced non-small cell lung cancer (NSCLC) patients. Before making treatment decisions, test for all 10 genomic biomarkers recommended by…

Watch this 1-minute video clip entitled "Breast Cancer Patient Case" where the Guardant360 test was used, resulting in the patient responding well to treatment. The findings from this case were presented by Dr. Shaheenah Dawood, a…

Watch this 2-minute video clip entitled "Findings from the plasmaMATCH study" where the Guardant360 test was used for patients with advanced stage breast cancer. These findings were presented by Dr. Shaheenah Dawood, a distinguished medical oncologist…

Breast cancer is the most common cancer in women worldwide. To address this issue, Guardant Health AMEA has increased access of the Guardant360® test to 41 countries in Asia, Middle East and Africa. Our FDA-approved…

Our Chief Medical Officer, Dr. Steve Olsen, sharing his thoughts on the use of the Guardant360 test in the plasmaMATCH trial and how it can help guide treatment decisions for advanced stage breast cancer patients. Visit…

Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and…

Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and…

A new study published in Nature Medicine led by the National Cancer Center Hospital East in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial…

The Guardant360 test is helping advanced breast cancer patients get the right treatment with a simple blood draw. In this patient case, the Guardant360 test detected a treatable alteration, PIK3CA, in a 45-year-old breast cancer…

Check out Guardant Health Inc.’s new product website at guardant360cdx.com. Find out how our test can help treat at the speed of cancer. Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling of…

Watch this live interview on CNBC Squawk Box Asia where our CEO, Simranjit Singh talks about Guardant Health AMEA’s growth strategy for the next two years and the advantages of using liquid biopsies such as the FDA-approved…

Inviting all medical oncologists! Join us on 25 Sep at 1pm for a Webinar Panel Discussion on the Role of Comprehensive Liquid Biopsy NGS in Treatment Planning for Advanced Cancer Management. Sign up here: https://lnkd.in/gCypxXh. This…

Calling All Pharmaceutical Industry Professionals! Join us on 18 September at 1pm (GMT+9hrs) for a Webinar Discussion on "Applications of liquid biopsy technology to accelerate oncology drug development". This webinar will feature a leading medical…

Watch this short video of our CEO, Simranjit Singh, talking about the use of Guardant360®in clinical trials and how we are very happy to be part of a recently launched initiative in Singapore called Project EISE…

Listen to this 5-minute radio interview with a leading Malaysian oncologist, Dato Dr Mohamed Ibrahim Abdul Wahid, talking about the use of liquid biopsies, like the Guardant360® test, and targeted therapy in cancer treatment. https://lnkd.in/gYRZcPt To…

Calling All Pharmaceutical Industry Professionals! Join us on 18 September at 1pm (GMT+9hrs) for a Webinar Discussion on "Applications of liquid biopsy technology to accelerate oncology drug development". This webinar will feature a leading medical…

Hear what Prof. David Gandara, MD, a world-renowned oncologist, has to say about Guardant360® CDx becoming the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers. This one-minute video…

Listen to GH AMEA’s CEO, Simranjit Singh, speaking about Using Guardant360® for advanced stage cancer patients during the Covid-19 pandemic.  Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy.…

Here’s a short video of GH AMEA’s CEO, Simranjit Singh, speaking about Guardant Health’s Guardant360® CDx FDA Approval.  Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you…

"This FDA approval is a significant milestone for Guardant Health AMEA and it will certainly boost our efforts in offering Guardant360® as the first FDA approved tumor mutation profiling liquid biopsy test for Solid cancers…

Guardant360® CDx receiving FDA Approval is a landmark achievement for us. For advanced cancer patients in Asia, Middle East & Africa, this FDA approval lends even greater credibility to the test and its ability to…

 Breaking news: Guardant Health's Guardant360® CDx is the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, advancing precision oncology in Asia, Middle East and Africa. This…

The U.S. Food and Drug Administration has approved the first liquid biopsy companion diagnostic, Guardant Health's Guardant360® CDx, that uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal…

Breaking news: Guardant Health's Guardant360® CDx is the first liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, advancing precision oncology in Asia, Middle East and Africa. This FDA…

Inviting all medical oncologists! Join us for a Webinar Discussion on how recent ASCO updates influence lung cancer biomarker testing and treatment. This webinar will feature a renowned medical oncologist, Prof. David Gandara, MD. from the…

 From all of us at Guardant Health AMEA, in observance of World Lung Cancer Day today. Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you…

Guardant Health, Inc. has announced a strategic collaboration with Radius Health, Inc. to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader (SERD) being…

Calling all medical oncologists! Join us for a Webinar Discussion on "The Algorithm to effectively use CGP with liquid as a tool in advanced lung cancer". This webinar on 29 July will feature two renowned…

Calling all medical oncologists! Join us for a Webinar Discussion on "The Algorithm to effectively use CGP with liquid as a tool in advanced lung cancer". This webinar on 29 July will feature two renowned…

 In the NILE Study, the Guardant360® test results showed more than 90% agreement with tissue for targetable genomic alterations. Actionable tumor mutations missed during tissue biopsies can be detected by our comprehensive liquid biopsy.…

Guardant Health, Inc. has announced a strategic collaboration with Janssen Biotech, Inc. to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied…

Inviting all medical oncologists! Join us for a Webinar Discussion on Blood vs Tissue Biopsy: How Do They Compare? This webinar will feature two leading medical oncologists, Dr. Natasha B. Leighl from Canada & Dr.…

 In the NILE study, Guardant360® detected more guideline-recommended biomarkers than tissue testing. Click on the video to find out more. Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in…

Calling all medical oncologists! Join us on 3 July at 4.30 pm (Indian Standard Time) for a webinar discussion on Clinical application of Liquid Biopsy - An Indian perspective. This webinar will feature Dr. Amit…

Asia Pacific Medical Technology Association (APACMed) has just appointed our CEO, Simranjit Singh, as the Vice-Chair for Diagnostics in their Start-Up Committee Leadership Team. https://lnkd.in/eSD-vbV

 The Guardant360® test provided comprehensive genomic profiling information for a patient with stage four lung cancer. The resulting treatment decisions saw a positive response from the patient. Click on the video to find out…

Guardant Health, Inc. addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. Click on the press release link below…

 Guide treatment decisions with Guardant360® test results which provide comprehensive genomic profiling information for your advanced stage cancer patients. Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy.…

Guardant Health, Inc. presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer…

Inviting all medical oncologists! Join us on 25 June for a webinar discussion on the Asian Perspective on Clinical Application of Comprehensive Genomic Profiling for Lung Cancer. This webinar will feature Prof. Tony Mok, a leading…

 Test your advanced stage cancer patients with Guardant360®, get results in approximately 7 days upon sample receipt in the laboratory and take action with first-line treatment. Visit us online @ guardanthealthamea.com to find out more about…

Calling all medical oncologists! Join us for a Molecular Tumor Board Webinar Discussion on Gastrointestinal Cancer. This webinar will feature four distinguished medical oncologists, Dr. Clara Montagut from Spain, Dr. Tobias Arkenau from U.K. and Dr. Shaheenah Dawood from U.A.E., who…

The Guardant360® test has been ordered over 100,000 times by more than 7,000 oncologists worldwide and has been validated in over 150 peer-reviewed publications. Our liquid biopsy test can help guide treatment decisions and favourably…

Prof. Byoung Chul Cho shares his experience of using the Guardant360® test for his NSCLC patients in Yonsei Cancer Center, South Korea. Check out this article from MIMS Pte Ltd. Visit us online @ guardanthealthamea.com to find out…

Dr. Vassiliki Papadimitrakopoulou on results from the NILE study, for patients with newly diagnosed advanced stage non-squamous NSCLC: “The most important finding was that liquid biopsy detects… genomic alterations at similar rates with tissue testing,…

Check out this press release on how Guardant360® test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients, according to the researchers at Samsung Medical Center in Seoul, Korea.…

Visit the ASCO20 Virtual Scientific Program online @ https://meetings.asco.org/ from 29 May to 31 May 2020 to view poster presentations from Guardant Health AMEA. Congratulations to all the investigators who contributed to the ASCO poster…

“I believe in many settings, liquid biopsy Guardant360-based test results are more reliable than tissue-based testing,” said Dr. Balazs Halmos, Director of Thoracic Oncology and Professor of Medicine at Montefiore Health System. Another medical oncologist…

Have A Happy Eid! - from all of us at guardanthealthamea.com

Our turnaround time for blood sample results has been maintained at approximately 7 days upon receipt in our laboratory. By working flexibly with different courier companies, we are able to serve your patients’ needs without…

Inviting all medical oncologists! Join us for a Webinar Discussion on the Use of Liquid Biopsy in Non-Small Cell Lung Cancer led by Prof. James Chih-Hsin Yang, Director of the Department of Oncology from National Taiwan…

Check out this Channel NewsAsia article featuring our CEO, Simranjit Singh, sharing his views on how liquid biopsies may provide a safer and more efficient alternative to invasive interventional procedures and reduce the need for cancer patients to…

Calling all medical oncologists! Join us tomorrow for a Molecular Tumor Board Webinar on Breast Cancer. This webinar will feature two distinguished medical oncologists, Dr. Shaheenah Dawood from U.A.E. who will be the main speaker and Dr. Bhawna…

JNCCN has released an invited article from the NCCN Best Practices Committee entitled “Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe.” With regards to diagnostics…

To all the nurses working in hospitals during this pandemic, thank you for the wonderful work that you do. Happy International Nurses Day! - from all of us at guardanthealthamea.com.

During this pandemic, you need a safe and non-invasive liquid biopsy like Guardant360® to guide treatment decisions for your advanced cancer patients. As hospital resources are currently over-burdened, scheduling tissue biopsies can be difficult and…

Happy Vesak Day! - from all of us at guardanthealthamea.com

Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for patients with metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimens. Tucatinib-based treatment improved overall…

Calling all medical oncologists! Join us for a Molecular Tumor Board Webinar on Breast Cancer on 15 May 2020. This webinar will feature two distinguished medical oncologists, Dr. Shaheenah Dawood from U.A.E. who will be the main…

The Guardant360® assay has been recently featured on the MIMS Oncology website in an article entitled "Liquid biopsy in the management of solid tumors". https://lnkd.in/fhuRH6D Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global…

Congratulations to Pfizer on their US FDA approval of Braftovi (encorafenib) in combination with cetuximab for previously treated metastatic colorectal cancer patients whose tumors are positive for BRAF V600E. It's great to have a new…

Calling all medical oncologists! Join us for an online debate entitled Blood vs Tissue Biopsy on 29 April 2020. This discussion features the following speakers: Dr. Herbert Loong from Hong Kong and Dr. Beung-Chul Ahn…

Happy Tamil New Year! - from all of us at guardanthealthamea.com

Happy Vaisakhi - from all of us at guardanthealthamea.com

Happy Easter! - from all of us at guardanthealthamea.com.

Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. A new study led by Memorial Sloan Kettering Cancer Center and published…

Today marks World Health Day. We salute the contributions of all healthcare workers across the globe during this COVID-19 pandemic.

We practise social distancing at work during this COVID-19 pandemic. Visit us at guardanthealthamea.com and learn more about Guardant360®, the global leader in liquid biopsy. Guardant360®. Test. Take Action.

Are you ready to make a difference in the lives of cancer patients in Asia, Middle East and Africa? Join our team at guardanthealthamea.com.

Looking forward to the live webinar discussion tonight led by Dr Cho Byoung Chul from Yonsei Cancer Centre, sharing his experience with the Guardant360® assay. If you are a medical oncologist who would like to…

A big heartfelt Thank You to all health care professionals during this COVID-19 pandemic - from all of us at guardanthealthamea.com.

Check out what this leading medical oncologist has to say about the use of liquid biopsies in lung cancer. Dr Nicholas Roh from Mount Sinai Hospital, New York, said, “I think liquid biopsy is one…

Happy International Women's Day from all of us at guardanthealthamea.com

If you are a medical oncologist, contact us at press@guardantamea.com to join us on 4 March 2020 for a zoom webinar discussion with Dr Steve Olsen on clinical applications of liquid biopsy. Visit us online @ guardanthealthamea.com to…

Join our team at guardanthealthamea.com and make a difference in the lives of cancer patients in Asia, Middle East and Africa.

Have you saved Guardant Health AMEA's WhatsApp Hotline Number? Contact us at +65 8940 0360 to find out about Guardant360®, the global leader in liquid biopsy. Guardant360®. Test. Take Action. Visit us online @ guardanthealthamea.com.

 Listen to what this leading medical oncologist has to say about actionable biomarkers... Dr Balazs Halmos said, "Nowadays, we just need to make sure that we leave no drivers behind. By now, we have…

Guardant Health was recently featured in Smithsonian Magazine, highlighting how simple blood draws could revolutionize cancer treatment. A 49-year-old advanced stage lung cancer patient, Ms Star Dolbier, whose oncologist ordered the Guardant360® test said, "I’m…

A regional advisory board meeting was recently held in Dubai on 14 February to discuss liquid biopsies. Our flagship product, the Guardant360® assay, was extensively discussed at this meeting. Visit us at guardanthealthamea.com to find…

 Hear what this leading medical oncologist has to say about liquid biopsy… Dr Vassiliki Papadimitrakopoulou sharing highlights of the “NILE study which was a prospective clinical trial comparing standard-of-care tissue testing for patients with…

 We, at guardanthealthamea.com, pledge our support for World Cancer Day. Order the Guardant360® test today for your advanced stage cancer patients and join us in this fight against cancer.

Guardant Health, Inc. and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005 study to validate the clinical utility of Guardant Health’s…

Guardant Health, Inc. and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005 study to validate the clinical utility of Guardant Health’s…

Team-building our way into 2020 at Resorts World Sentosa in Singapore. Visit us online at guardanthealthamea.com to find out more about us and our flagship product, Guardant360®, the global leader in liquid biopsy. Guardant360®. Test.…

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East & Africa and get your results in approximately 7 days upon sample receipt in the laboratory. Visit us at…

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Here…

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Here…

Guardant Health AMEA is honoured to sign an MOU with the Yonglin Healthcare Foundation, which is dedicated to fight cancer in Taiwan. We are also part of their clinical studies for advanced lung cancer and…

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Here…

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Here…

Watch the video below for clinical evidence to support the use of the Guardant360® test for advanced breast cancer patients. Order the test online today at guardanthealthamea.com. Guardant360®. Test. Take Action.

Order the Guardant360® test online today for your advanced stage cancer patient in Asia, Middle East and Africa. Visit us at guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Here…

We, at Guardant Health Asia, Middle East and Africa (AMEA), have just launched our new website to make it easier for oncologists and advanced stage cancer patients to find out more information about us online.…

With a simple blood draw from your advanced stage cancer patient, you will be able to make quicker, better informed and more personalized treatment decisions as a physician. How is this made possible? The Guardant360®…

We, at Guardant Health Asia, Middle East and Africa (AMEA), have just launched our new website to make it easier for oncologists and advanced stage cancer patients to find out more information about us online.…

Visit the Guardant Health AMEA Team today at our ESMO Asia Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Visit us today at our ESMO Asia Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

We, at Guardant Health Asia, Middle East and Africa (AMEA), have just launched our new website to make it easier for oncologists and advanced stage cancer patients to find out more information about us online.…

Our brand new website for Guardant Health Asia, Middle East and Africa (AMEA) has officially gone “live”. Visit us today at https://www.guardanthealthamea.com. With this launch, we aim to create awareness among oncologists and advanced cancer…

Visit us today at our ESMO Asia Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Guardant360®-first testing is able to identify more patients who are eligible for targeted treatments than tissue-first testing. Here are the key findings from the NILE study reported earlier this year. - Agreement between Guardant360® and…

1 week to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Join us at our poster display session at ESMO Asia 2019 on 23 Nov 2019 in Suntec Singapore Convention & Exhibition Centre from 6pm to 7pm and learn more about Guardant360®, the global leader in…

You deserve to know the comprehensive profile of your cancer genomics. Comprehensive genotyping using a simple blood draw can help you get the most appropriate treatment. This is clearly illustrated in the real life example…

2 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

[vc_row][vc_column][vc_column_text]Want to avoid complications and delays of invasive tissue-based tests? Our liquid biopsy option has consistently high agreement with tissue-based testing. Click the video below to find out how you can select the right cancer…

3 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Guardant Health, Inc. has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its LUNAR-2 blood test to detect colorectal cancer (CRC) in average-risk adults. The test is intended to improve…

Testing for Microsatellite Instability-High (MSI-High) can help you make more informed immunotherapy treatment decisions for your advanced stage cancer patients. This is clearly illustrated in the real life example of an advanced stage metastatic colorectal…

4 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Certain cancer therapies provide better patient outcomes but an individual’s response to a given treatment often depends on the tumor’s genomic profile. The Guardant360® assay provides comprehensive genomic results from a simple blood draw in…

5 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Looking for treatment options for advanced stage cancer? Want to avoid complications and delays of invasive tissue-based tests? Check out these findings of the NILE Study below of how you can select the right cancer…

6 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

If you would like to recommend a comprehensive genomic profiling test for your advanced stage cancer patient, click the video below to find out why you should order Guardant360®, the global leader in liquid biopsy.

If you are a physician looking to order a comprehensive genomic profiling test for an advanced stage cancer patient, here is why you should consider Guardant360®, the global leader in liquid biopsy.

Guardant Health AMEA and Genconn Biotech announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in Taiwan. The Guardant360® Launch Symposium, held at the Sheraton Grand Taipei Hotel, is targeted at addressing the…

7 weeks to go to ESMO Asia 2019. Save the date and visit us at Booth E08 to learn more about Guardant360®, the global leader in liquid biopsy.

Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) -- Guardant Health and the National Cancer Center Hospital East will present data…

Guardant Health AMEA will be presenting four Poster Displays in the annual European Society for Medical Oncology Congress, taking place in Barcelona from 27th September to 1st October 2019. Here are the details of the…

Guardant Health AMEA will also be presenting one Poster Discussion and two Proffered Papers in the annual European Society for Medical Oncology Congress, taking place in Barcelona from 27th September to 1st October 2019. Here…

Guardant Health AMEA is pleased to be part of the conference delegation in the upcoming World Conference on Lung Cancer, taking place in Barcelona from 7th to 10th September 2019. With the global lung cancer…

Renewing Hope in the Fight Against Cancer “No longer a death sentence”: Last year, 18 million people around the world were diagnosed with cancer. We’re looking to China to become their beacon of hope. #TemasekReview…

Advanced diagnostics such as comprehensive genomic profiling using liquid biopsy can accelerate drug development and help treatment selection for patients,” said Guardant Health AMEA CEO, Mr Simranjit Singh, in his keynote address at the BIO…

Guardant Health AMEA CEO, Mr Simranjit Singh, will be sharing his views on the trends and future of precision oncology at the 2019 BIO Asia-Taiwan Conference and Exhibition at 9am on 25 July in Taipei.…

“Guardant Health AMEA is pleased to launch the Guardant360® assay in South Korea to help cancer patients get the right cancer treatment with our breakthrough liquid biopsy. Guardant360® also offers physicians and patients rapid access…

Guardant Health AMEA CEO, Mr Simranjit Singh, shared his insights with Temasek on the burden of cancer in China and how liquid biopsies can help physicians select effective treatments for their patients. Source: https://www.temasekreview.com.sg/our-stories/chinas-push-against-cancer.html

Come and visit us at booth #17108. #ASCO19

"The global burden of cancer is devastating. There were 18.1 million new cases of cancer in 2018 and half of them were in Asia. There were more than 5.4 million cancer deaths in Asia, which…

Guardant Health AMEA would be in #asco2019. Come and join us at booth 17108

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology…

Come and visit us at APGCS 2019 in Shangri-La Hotel

Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer Purpose: Complete and timely tissue genotyping is challenging, leading to significant numbers of patients…

We would be participating in the coming Asia Pacific Gastroenterology Cancer Summit 2019. Come and visit us at the booth to learn more about Guardant360®

We are proud to share our CEO, Mr. Simranjit Singh has recently been appointed to the National Health Innovation Centre Oversight committee under the Ministry of Health as an Industry representative. The National Health Innovation…

Our heartfelt Thank You and Appreciation to Singapore Cancer Society, Ms. Chun Wee Ping and everyone who has extended your immerse effort and kind generosity in helping cancer patients and their families. Presenting our final…

Featured in Business Times today - We look forward to work with more oncologists to provide Targeted Therapies for Advanced Cancer patients! https://lnkd.in/fK8s9np

Nasdaq-listed medical tech firm Guardant Health has opened its Asia, Middle East and Africa (AMEA) regional headquarters here. Guardant Health helps doctors decide which therapy may be effective for advanced-stage cancer patients with solid tumours,…

This online auction is part of the fundraiser event organized by Guardant Health AMEA in support of Singapore Cancer Society (SCS) to extend our greatest support to cancer patients in their journey to recovery. We…

Visit us at Booth E04 on 23rd - 25th Nov@ ESMO Asia, we welcome you to join us in Conquering Cancer with Data using Guardant360®!

Prof. David Gandara speaking about the IASLC Consensus Statement on Liquid Biopsy

How can liquid biopsies like Guardant360®️ help guide treatment decisions for advanced stage cancer?